Watchlist

Watchlist
Rigel Pharmaceuticals, Inc. (RIGL)
Rigel Pharmaceuticals, Inc. (RIGL)
EMA accepts Rigel's marketing application for fostamatinib for immune thrombocytopenia; shares up 2% premarket
Rigel Pharmaceuticals (NASDAQ: RIGL ) is up 2% premarket on light volume on the heels of its announcement that the European Medicines Agency (EMA) has accepted for review its marketing application seeking approval for fostamatinib for the treatment of adult patients with chroni…
Rigel Receives EMA Validation of the Marketing Authorization Application for Fostamatinib Disodium Hexahydrate in Chronic Immune Thrombocytopenia (ITP) in Adult Patients
SOUTH SAN FRANCISCO, Calif. , Oct. 11, 2018 /PRNewswire/ --Rigel Pharmaceuticals, Inc.(Nasdaq: RIGL) todayannounced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for fostamatinib in adult chronic immune thrombocytope…
Rigel Pharmaceuticals, Inc. (RIGL)